• Our Company
  • Our Mission & Commitment
  • Key Facts
  • Leadership
  • Governance
  • History
  • Compliance & Ethics
  • Diversity & Inclusion
  • Our Websites
  • Achievements
  • Business Information
• R&D
  • R&D Strategy
  • In the Pipeline
  • Investigational Compound News
  • Disease Areas of Focus
  • Our R&D
  • Our Science
  • R&D Highlights
  • Major R&D Facilities
  • Clinical Trials
• Products
  • Patient Assistance Programs
  • Prescribing Information
  • R&D
  • Clinical Trials
  • Counterfeit Drugs
  • Product Information Inquiries
• News
  • Press Releases
  • Publications
  • Media Library
  • Key Facts
  • Leadership
  • Financial Reporting
  • Features
  • Achievements
  • Media Contacts
  • Subscribe to e-mail alerts
• Investors
  • Key Facts
  • Stock Information
  • SEC Filings
  • Financial Reporting
  • Events & Presentations
  • Shareholder Services
  • Investor Contacts
• Partnering
  • Why Partner With Us?
  • Areas of Interest
  • Our Process
  • Our Partners
  • Partnering News
  • Partnering Contact
• Responsibility
  • Bristol-Myers Squibb Foundation
  • Sustainability
  • Patient Assistance Programs
  • Building Our Communities
  • Grants & Giving
  • Position on Key Issues
  • Clinical Trials
  • Combating Counterfeit Drugs
  • Achievements
• Careers
  • Job Opportunities
  • Our Culture
  • Diversity & Inclusion
  • Developing Our People
  • University Recruitment
  • Achievements
  • Benefits
  • Manage My Profile
  • Apply Now

BMS.com Home » Research » Investigational Compound News

Learn more about Bristol-Myers Squibb’s research and development efforts and track the progress of investigational compounds in the news. Our pipeline is one of the most innovative in the industry.

We will post periodic updates about select Phase 1 and 2 investigational compounds on this page, as new data are presented or published.

BMS-901608 (anti-CS1 antibody)
American Society of Clinical Oncology (ASCO), June 2010
Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase I/II Study

BMS-790052 (NS5A inhibitor)
European Association for the Study of the Liver (EASL), April 2010
Once-Daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-Alpha-2A and Ribavirin Produces High Rates of Extended Rapid Virologic Response in Treatment-Naïve HCV-Genotype 1 Subjects: Phase 2A Trial

To receive notifications when updates to this page are available, media and investors can sign for our “Investigational Compound News” RSS feed.

Get RSS News Alerts